|
"chiu cf"的相關文件
顯示項目 1-10 / 115 (共12頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-10-28 |
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: A real-world study in breast cancer patients in Taiwan
|
Wang, SC;Shen, YC;Pan, MR;Ou-Yang, F;Liao, TY;Liu, LC;Rau, KM;Lu, LS;Huang, CC;Dai, MS;Lu, YS;Chang, HW;Chang, H;Chang, KP;Wang, J;Tsai, CJ;Chou, IW;Li, HW;Cheng, WC;Li, TC;Cha, TL;Liao, GS;Chiu, CF;Huang, CS;Tseng, LM;Chiou, JF;Sheen-Chen, SM;Hou, MF;Hung, MC |
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2025-06-04 |
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
|
Chiang, NJ;Bai, LY;Ho, IW;Hsu, CH;Liang, YH;Chiu, CF;Lin, CC;Chang, KY;Chen, SH;Tsai, HJ;Lin, YP;Chen, LT;Lin, CC |
| 國家衛生研究院 |
2025-03-27 |
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells[Erratum:Experimental and Molecular Medicine. 2024 Sep 18;56:2065-2081.]
|
Park, JM;Su, YH;Fan, CS;Chen, HH;Qiu, YK;Chen, LL;Chen, HA;Ramasamy, TS;Chang, JS;Huang, SY;Chang, WW;Lee, AY;Huang, TS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2025-02-10 |
FOXO3a/miR-4259-driven LDHA expression as a key mechanism of gemcitabine sensitivity in pancreatic ductal adenocarcinoma
|
Hsu, TW;Wang, WY;Chen, HA;Wang, TH;Su, CM;Liao, PH;Chen, AL;Tsai, KY;Kokotos, G;Kuo, CC;Chiu, CF;Su, YH |
| 國家衛生研究院 |
2024-09-18 |
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells
|
Park, JM;Su, YH;Fan, CS;Chen, HH;Qiu, YK;Chen, LL;Chen, HA;Ramasamy, TS;Chang, JS;Huang, SY;Chang, WSW;Lee, AYL;Huang, TS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2024-09 |
TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
|
Su, YY;Bai, LY;Huang, CJ;Chiu, CF;Wang, HT;Du, JS;Wang, HC;Chuang, S;Shih, YH;Lin, HC;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2024-03 |
The cross-talk between FTH1 & PYCR1 plays a pivotal role in driving the progression of KRAS-mutated pancreatic cancer
|
Park, J;Qiu, YK;Su, YH;Chen, HA;Lee, AL;Chang, JS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
顯示項目 1-10 / 115 (共12頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
